PMID- 33489802
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220420
IS  - 2218-6751 (Print)
IS  - 2226-4477 (Electronic)
IS  - 2218-6751 (Linking)
VI  - 9
IP  - 6
DP  - 2020 Dec
TI  - Survival benefit and toxicity profile of adjuvant icotinib for patients with EGFR 
      mutation-positive non-small cell lung carcinoma: a retrospective study.
PG  - 2401-2410
LID - 10.21037/tlcr-20-1214 [doi]
AB  - BACKGROUND: Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase 
      inhibitors (TKIs) are increasing considered for the tailored management of 
      resectable non-small cell lung cancer (NSCLC). This study aimed to analyze the 
      survival and toxicity profile of patients with EGFR mutation-positive NSCLC 
      treated with adjuvant icotinib. METHODS: This was a single-center retrospective 
      study of patients with EGFR mutation-positive NSCLC who underwent R0 
      (microscopically margin-negative) resection and received adjuvant icotinib 
      between November 2011 and December 2017. The outcomes included 2-year 
      disease-free survival (DFS) rate, 3-year overall survival (OS) rates, DFS, OS, 
      and adverse events (AEs). RESULTS: A total of 86 patients receiving adjuvant 
      icotinib were included. Their mean age was 59.7+/-10.0 years, and 26 (30.2%) 
      patients were male. The 2-year DFS rate was 86.7%, and the 3-year OS rate was 
      95.3% with adjuvant icotinib. DFS (P=0.044) and OS (P=0.003) are better in stage 
      I/II disease than in stage III disease. There seems no differences in DFS and OS 
      between patients with low or high preoperative CEA levels (cutoff of 5 ng/mL), 
      patients with exon 19 or 21 EGFR mutation or patients with or without smoking 
      history. The most common AEs with adjuvant icotinib were rash (83.7%) and 
      diarrhea (19.8%). One (1.2%) patient-reported grade >/=3 AEs. No treatment-related 
      death occurred. CONCLUSIONS: For patients with EGFR mutation-positive NSCLC, 
      adjuvant icotinib might be associated with a promising survival benefit, with an 
      acceptable toxicity profile.
CI  - 2020 Translational Lung Cancer Research. All rights reserved.
FAU - Zeng, Ziqing
AU  - Zeng Z
AD  - Department of Immunology, Tianjin Medical University Cancer Institute and 
      Hospital, National Clinical Research Center for Cancer, Tianjin, China.
AD  - Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
AD  - Tianjin's Clinical Research Center for Cancer, Tianjin, China.
AD  - Tianjin Key Laboratory of Cancer, Immunology, and Biotherapy, Tianjin, China.
FAU - Yan, Bo
AU  - Yan B
AD  - Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
AD  - Department of Radiotherapy, Tianjin Medical University Cancer Institute and 
      Hospital, National Clinical Research Center for Cancer, Tianjin, China.
FAU - Chen, Yulong
AU  - Chen Y
AD  - Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
AD  - Department of Radiotherapy, Tianjin Medical University Cancer Institute and 
      Hospital, National Clinical Research Center for Cancer, Tianjin, China.
AD  - Department of Lung Cancer, Tianjin Medical University Cancer Institute and 
      Hospital, National Clinical Research Center for Cancer, Tianjin, China.
FAU - Zhang, Lianmin
AU  - Zhang L
AD  - Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
AD  - Department of Lung Cancer, Tianjin Medical University Cancer Institute and 
      Hospital, National Clinical Research Center for Cancer, Tianjin, China.
AD  - Tianjin's Clinical Research Center for Cancer, Tianjin Lung Cancer Center, 
      Tianjin, China.
FAU - Zhu, Jianquan
AU  - Zhu J
AD  - Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
AD  - Department of Lung Cancer, Tianjin Medical University Cancer Institute and 
      Hospital, National Clinical Research Center for Cancer, Tianjin, China.
AD  - Tianjin's Clinical Research Center for Cancer, Tianjin Lung Cancer Center, 
      Tianjin, China.
FAU - Yang, Fan
AU  - Yang F
AD  - Department of Immunology, Tianjin Medical University Cancer Institute and 
      Hospital, National Clinical Research Center for Cancer, Tianjin, China.
AD  - Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
AD  - Tianjin's Clinical Research Center for Cancer, Tianjin, China.
AD  - Tianjin Key Laboratory of Cancer, Immunology, and Biotherapy, Tianjin, China.
AD  - Department of Biotherapy, Tianjin Medical University Cancer Institute and 
      Hospital, Tianjin, China.
FAU - Wei, Feng
AU  - Wei F
AD  - Department of Immunology, Tianjin Medical University Cancer Institute and 
      Hospital, National Clinical Research Center for Cancer, Tianjin, China.
AD  - Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
AD  - Tianjin's Clinical Research Center for Cancer, Tianjin, China.
AD  - Tianjin Key Laboratory of Cancer, Immunology, and Biotherapy, Tianjin, China.
FAU - Tam, Terence Chi Chun
AU  - Tam TCC
AD  - Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong 
      Kong, China.
FAU - Kauffmann-Guerrero, Diego
AU  - Kauffmann-Guerrero D
AD  - Division of Respiratory Medicine and Thoracic Oncology, Department of Internal 
      Medicine V and Thoracic Oncology Centre Munich, University of Munich (LMU), 
      Comprehensive Pneumology Center, Member of the German Center for Lung Research 
      (DZL), Munich, Germany.
FAU - Soo, Ross Andrew
AU  - Soo RA
AD  - Department of Haematology-Oncology, National University Cancer Institute 
      Singapore, National University Health System, Singapore, Singapore.
FAU - Ren, Xiubao
AU  - Ren X
AD  - Department of Immunology, Tianjin Medical University Cancer Institute and 
      Hospital, National Clinical Research Center for Cancer, Tianjin, China.
AD  - Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
AD  - Tianjin's Clinical Research Center for Cancer, Tianjin, China.
AD  - Tianjin Key Laboratory of Cancer, Immunology, and Biotherapy, Tianjin, China.
AD  - Department of Biotherapy, Tianjin Medical University Cancer Institute and 
      Hospital, Tianjin, China.
FAU - You, Jian
AU  - You J
AD  - Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
AD  - Department of Lung Cancer, Tianjin Medical University Cancer Institute and 
      Hospital, National Clinical Research Center for Cancer, Tianjin, China.
AD  - Tianjin's Clinical Research Center for Cancer, Tianjin Lung Cancer Center, 
      Tianjin, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Transl Lung Cancer Res
JT  - Translational lung cancer research
JID - 101646875
PMC - PMC7815377
OTO - NOTNLM
OT  - Non-small cell lung cancer (NSCLC)
OT  - adjuvant
OT  - epidermal growth factor receptor mutation (EGFR mutation)
OT  - icotinib
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/tlcr-20-1214). The authors have no 
      conflicts of interest to declare.
EDAT- 2021/01/26 06:00
MHDA- 2021/01/26 06:01
PMCR- 2020/12/01
CRDT- 2021/01/25 05:43
PHST- 2021/01/25 05:43 [entrez]
PHST- 2021/01/26 06:00 [pubmed]
PHST- 2021/01/26 06:01 [medline]
PHST- 2020/12/01 00:00 [pmc-release]
AID - tlcr-09-06-2401 [pii]
AID - 10.21037/tlcr-20-1214 [doi]
PST - ppublish
SO  - Transl Lung Cancer Res. 2020 Dec;9(6):2401-2410. doi: 10.21037/tlcr-20-1214.